SEARCH

SEARCH BY CITATION

References

  • 1
    Sonnerborg AB, Ehrnst AC, Bergdahl SK, Pehrson PO, Skoldenberg BR, Strannegard OO. HIV isolation from cerebrospinal fluid in relation to immunological deficiency and neurological symptoms. AIDS 1988; 2: 8993.
  • 2
    Chang L. In vivo magnetic resonance spectroscopy in HIV and HIV-related brain diseases. Rev Neurosci 1995; 6: 365378.
  • 3
    Chang L, Ernst T, Leonido-Yee M, Walot I, Singer E. Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology 1999; 52: 100108.
  • 4
    Masliah E, Achim CL, Ge N, DeTeresa R, Terry RD, Wiley CA. Spectrum of human immunodeficiency virus-associated neocortical damage. Ann Neurol 1992; 32: 321329.
  • 5
    Masliah E, Ge N, Morey M, DeTeresa R, Terry RD, Wiley CA. Cortical dendritic pathology in human immunodeficiency virus encephalitis. Lab Invest 1992; 66: 285291.
  • 6
    Heaton RK, Marcotte TD, Mindt MR et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004; 10: 317331.
  • 7
    Ellis RJ, Hsia K, Spector SA et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol 1997; 42: 679688.
  • 8
    Letendre SL, McCutchan JA, Childers ME et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 2004; 56: 416423.
  • 9
    Fernandes Filho SM, de Melo HR. Frequency and risk factors for HIV-associated neurocognitive disorder and depression in older individuals with HIV in northeastern Brazil. Int Psychogeriatr 2012; 24: 16481655.
  • 10
    Robertson KR, Smurzynski M, Parsons TD et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007; 21: 19151921.
  • 11
    Cysique LA, Brew BJ. Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression. J Neurovirol 2011; 17: 176183.
  • 12
    Simioni S, Cavassini M, Annoni JM et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24: 12431250.
  • 13
    White DA, Heaton RK, Monsch AU. Neuropsychological studies of asymptomatic human immunodeficiency virus-type-1 infected individuals. The HNRC Group. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1995; 1: 304315.
  • 14
    Heaton RK, Clifford DB, Franklin DR, Jr et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75: 20872096.
  • 15
    Antinori A, Arendt G, Becker JT et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69: 17891799.
  • 16
    Smurzynski M, Wu K, Letendre S et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011; 25: 357365.
  • 17
    Zung WW. A self-rating depression scale. Arch Gen Psychiatry 1965; 12: 6370.
  • 18
    Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 1984; 53: 20022007.
  • 19
    1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 119.
  • 20
    Amico KR, Fisher WA, Cornman DH et al. Visual analog scale of ART adherence: association with 3-day self-report and adherence barriers. J Acquir Immune Defic Syndr 2006; 42: 455459.
  • 21
    Sacktor NC, Wong M, Nakasujja N et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005; 19: 13671374.
  • 22
    Lee JY, Dong Woo L, Cho SJ et al. Brief screening for mild cognitive impairment in elderly outpatient clinic: validation of the Korean version of the Montreal Cognitive Assessment. J Geriatr Psychiatry Neurol 2008; 21: 104110.
  • 23
    Yeom TH, Park YS, Oh KJ, Lee YH. Korean Version Wechsler Adult Intelligence Scale. Seoul, Korea Guidance, 1992.
  • 24
    Kim M, Hyun MH. Relationships between Trail Making Test (A, B, B-A, B/A) scores and age, education, comparison of performance head injury patient and psychiatric patient, The Korean. J Clin Psychol 2004; 23: 353366.
  • 25
    Kim HK. Rey-Kim Memory Test. Seoul, Publishing Neuropsychology, 1999.
  • 26
    Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G. Wisconsin Card Sorting Test Manual, Revised and Expanded. Odessa, FL, Psychological Assessment Resources, Inc., 1993.
  • 27
    Lee TY. Normative values for the Grooved Pegboard Test in Adult. Phys Ther Kor 2001; 8: 8794.
  • 28
    Woods SP, Rippeth JD, Frol AB et al. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol 2004; 26: 759778.
  • 29
    Njamnshi AK, Bissek AC, Ongolo-Zogo P et al. Risk factors for HIV-associated neurocognitive disorders (HAND) in sub-Saharan Africa: the case of Yaounde-Cameroon. J Neurol Sci 2009; 285: 149153.
  • 30
    McArthur JC, Hoover DR, Bacellar H et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 1993; 43: 22452252.
  • 31
    Ciccarelli N, Fabbiani M, Di Giambenedetto S et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011; 76: 14031409.
  • 32
    Letendre S, Marquie-Beck J, Capparelli E et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 6570.
  • 33
    Ellis RJ, Badiee J, Vaida F et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 2011; 25: 17471751.
  • 34
    Valcour V, Yee P, Williams AE et al. Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection – The Hawaii Aging with HIV Cohort. J Neurovirol 2006; 12: 387391.
  • 35
    McCombe JA, Vivithanaporn P, Gill MJ, Power C. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care. HIV Med 2013; 14: 99107.
  • 36
    Lawler K, Mosepele M, Ratcliffe S et al. Neurocognitive impairment among HIV-positive individuals in Botswana: a pilot study. J Int AIDS Soc 2010; 13: 15.
  • 37
    Nasreddine ZS, Phillips NA, Bedirian V et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695699.
  • 38
    Bryden PJ, Roy EA. A new method of administering the Grooved Pegboard Test: performance as a function of handedness and sex. Brain Cogn 2005; 58: 258268.
  • 39
    Davis HF, Skolasky RL, Jr, Selnes OA, Burgess DM, McArthur JC. Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read 2002; 12: 2931, 38.
  • 40
    Korea Centers of Disease Control and Prevention. 2011 Annual Report on the Notified HIV/AIDS in Korea. PHWR 2012; 5: 1114.